Merck & Co., Inc. (MRK) Guidance & Earnings Results
On 2026-04-30 Merck & Co., Inc. raised guidance: "Full-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS raised to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MRKMerck & Co., Inc.Follow MRK — free
—
Price chart with a free account
- Market cap
- 358.4B
- P/E TTM
- 115.3
- Dividend yield
- 2.3%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 30 Apr 26 | Raised | Full-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS raised to $5.04-$5.16 · full year |
Merck & Co., Inc. — questions
- What guidance did Merck & Co., Inc. give?
- On 2026-04-30: "Full-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS raised to $5.04-$5.16"
- When does Merck & Co., Inc. report earnings?
- Merck & Co., Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Merck & Co., Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.